ClinicalTrials.gg
CompletedNCT00966875Updated May 26, 2016Results posted

A Study in Patients With Rheumatoid Arthritis

A Phase 2 interventional study of LY2439821 and Placebo in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 75 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-05-26.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
448
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Eli Lilly and Company.

Enrollment
13th of 35
448 · median 164
Started
2009
with 2 others
Phase 2
13 of 35
none open now
Registered
6th of 35
by date

Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, this one is the 13th largest by enrollment, is one of 3 that started in 2009, is one of 13 in phase 2, and was the 6th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, or all of them as a file.
02

Study summary

The primary purpose of the study is to help answer the following research questions, and not to provide treatment for Rheumatoid Arthritis (RA):

  • The safety of LY2439821 and any side effects that might be associated with it.
  • Whether LY2439821 can help participants with active RA.
  • How much LY2439821 should be given to participants.
Read the detailed description

Study I1F-MC-RHAK is a multicenter study in participants with active RA on concomitant conventional DMARD therapy. The study is a Phase 2 study with 2 parts. Part A is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging design and Part B is an optional, open-label extension design. Two participant populations will be evaluated in this study: bDMARD-naive participants and TNFα-IR participants. Participants in Part A receive multiple subcutaneous injections of LY2439821 [bDMARD-naive participants: 0 (placebo), 3, 10, 30, 80, or 180 mg; TNFα-IR participants: 0 (placebo), 80 or 180 mg] at Weeks 0, 1, 2, 4, 6, 8, and 10. Participants in Part B receive subcutaneous injections of LY2439821 160 mg at Weeks 16, 18, and 20, and every 4 weeks thereafter through Week 60. Participants who complete both Part A and B have a total study participation of up to approximately 72 to 84 weeks.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • rheumatoid arthritis
  • RA
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • You must be between the ages of 18 and 75
  • You must have active RA

Qualifications Specific to the bDMARD-naive Population:

You must be regularly using methotrexate (MTX) for at least 12 weeks before your participation in this study

Qualifications Specific to the TNFα-IR Population:

  • You must have been treated with at least 1 biologic TNFα inhibitor therapy and either had an insufficient response to at least 3 months of treatment OR have been intolerant of such treatment
  • You must be regularly using at least 1 conventional DMARD in a stable treatment regimen

Exclusion Criteria:

  • You are concomitantly using non-steroidal anti-inflammatory drugs (NSAIDS), unless you are on a stable dose within the last 2 weeks
  • You are a woman who is lactating or breast feeding
  • You have donated more than 300 milliliters (mL) of blood within the last month
  • You have received administered by intra-articular, intramuscular, or intravenous injection or oral corticosteroids at an average daily dose of greater than 10 mg per day of prednisone or its equivalent within the last 4 weeks
  • You had surgery on a joint that is to be assessed in the study within 2 months of study enrollment, or will require such during the study
  • You have another serious disorder or illness
  • You suffered a serious bacterial infection (for example, pneumonia, cellulitis, or bone or joint infections) within the last 3 months
  • You have a history of uncontrolled high blood pressure
  • You have clinical laboratory test results at entry that are outside the normal reference range
  • You are an employee of the clinic or you are an immediate family member of an employee of the clinic. Immediate family member is defined as a spouse, parent, child, or sibling, whether biological or legally adopted
  • You are currently participating in or were discontinued within the last 30 days from another clinical trial involving an drug
  • If you are a woman and you could become pregnant during this study, you must talk to the study doctor about the that you will use to avoid getting pregnant during the study.
  • If you are a woman, you must be at least 45 years of age and have not menstruated for the last 12 months
  • If you are a post-menopausal woman between 40 and 45 years of age, test negative for pregnancy, and have not menstruated during the last 12 months only, you must have an additional blood test to see if you can participate.
  • If you are male, you must agree to reduce the risk of your female partner becoming pregnant during the study.

Exclusions Specific to the bDMARD-naive Population:

  • You have received any prior bDMARD therapy such as TNFα, Interleukin (IL)-1, IL-6, T-cell, or B-cell targeted therapies
  • You have had an inadequate response to a minimum of 3 months of treatment with 5 or more conventional DMARDs [such as leflunomide, azathioprine, cyclosporine, etcetera (etc.)]
  • You have used DMARDs other than MTX, hydroxychloroquine, or sulfasalazine within the last 8 weeks
  • You have used leflunomide within the last 12 weeks and have not received cholestyramine to speed up the elimination of leflunomide from your body.

Exclusions Specific to the TNFα-IR Population:

  • You are currently using or recently used a bDMARD or a biologic TNFα inhibitor therapy within specified periods
  • You have had a serious reaction to other biologic DMARDs that, in the study doctor's opinion, puts you at serious risk
  • You have used cyclosporine or any other in the 8 weeks before your participation in this study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
448 participants (actual)

Study arms

  • Experimental
    3 mg LY2439821 (bDMARD-naive population)

    3 milligrams (mg) LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. \[Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD)\]

    Biological: LY2439821

  • Experimental
    10 mg LY2439821 (bDMARD-naive population)

    10 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.

    Biological: LY2439821

  • Experimental
    30 mg LY2439821 (bDMARD-naive population)

    30 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.

    Biological: LY2439821

  • Experimental
    80 mg LY2439821 (bDMARD-naive population)

    80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.

    Biological: LY2439821

  • Experimental
    180 mg LY2439821 (bDMARD-naive population)

    180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.

    Biological: LY2439821

  • Experimental
    80 mg LY2439821 (TNFa-IR population)

    80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. \[Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR)\]

    Biological: LY2439821

  • Experimental
    180 mg LY2439821 (TNFa-IR population)

    180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.

    Biological: LY2439821

  • Placebo comparator
    Placebo (bDMARD-naive population)

    Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.

    Drug: Placebo

  • Placebo comparator
    Placebo (TNFa-IR population)

    Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.

    Drug: Placebo

Interventions

  • BiologicalLY2439821

    Subcutaneous

    Also known as: ixekizumab

  • DrugPlacebo

    Subcutaneous

06

What researchers measure

Primary outcomes

  1. Dose-Response Relationship Measured by the Percentage of Participants With American College of Rheumatology (ACR) 20 Response in bDMARD-Naive Population

    ACR20 responders are participants with at least 20% improvement from baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: Health Assessment Questionnaire-Disability Index (HAQ-DI) which measured participants perceived degree of difficulty performing daily activities, C-reactive Protein (CRP), Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), Patient's Global Assessment of Disease Activity-VAS(PtGADA-VAS), and Physician's Global Assessment of Disease Activity-VAS (PhGA-VAS). Missing values were imputed using Non-Responder Imputation (NRI). Percentage of participants achieving ACR20 response was calculated as: (number of ACR20 responders / number of participants treated) \* 100.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants With ACR20 Response in Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR) Population

    ACR20 responders were participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants achieving ACR20 response was calculated as: (number of ACR20 responders / number of participants treated) \* 100.

    Time frame: Week 12

  2. Smallest Doses That Achieve 10%, 50%, and 90% of the Maximum ACR 20 Response in bDMARD-Naive Population

    ACR20 responders are participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. The model used in the dose response analysis was used to estimate the doses that achieved 10%, 50%, and 90% of the maximal drug efficacy. Missing values were imputed using NRI. The log transformed dose was evaluated.

    Time frame: Week 12

  3. Smallest Doses That Achieved 10%, 50%, and 90% of the Maximum Disease Activity Score (DAS) 28 Response in bDMARD-Naive Population

    DAS modified included the 28 diarthrodial joint count (DAS28) that consisted of a composite score of the following variables: TJC out of 28 (TJC28), SJC out of 28 (SJC28), CRP \[milligrams per liter (mg/L)\], and PtGADA on a 0 to 100 millimeter (mm) VAS ranging from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 was calculated as: DAS28 - CRP = 0.56(square root of TJC28) + 0.28(square root of SJC28) + 0.36(ln\[CRP +1\]) + 0.014(VAS) + 0.96.

    Time frame: Week 12

  4. Smallest Doses That Achieve 10%, 50%, and 90% of the Maximum ACR50 Response in bDMARD-Naive Population

    ACR50 responders were participants with at least 50% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI.

    Time frame: Week 12

  5. Change From Baseline in Disease Activity Score (DAS28)-Part A

    DAS28 consisted of a composite score of the following variables: TJC28, SJC28, CRP, and PtGADA-VAS. DAS28 was calculated as: DAS28 - CRP =0.56(square root TJC28) + 0.28(square root SJC28) + 0.36(ln\[CRP +1\]) + 0.014(VAS) + 0.96. A negative change indicated an improvement.

    Time frame: Baseline, up to Week 12

  6. Change From Baseline in DAS28 - Part B

    DAS28 consisted of a composite score of the following variables: TJC28, SJC28, CRP, and PtGADA-VAS. DAS28 was calculated as: DAS28 - CRP =0.56(square root TJC28) + 0.28(square root SJC28) + 0.36(ln\[CRP +1\]) + 0.014(VAS) + 0.96. A negative change indicated an improvement.

    Time frame: Baseline, Week 64

  7. Percentage of Participants With ACR20/50/70 Response - Part A

    ACR20 (or ACR50 or ACR70) responders were participants with at least 20% (or 50% or 70%, respectively) improvement from baseline TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants was calculated as: (number of ACR20 \[or ACR50 or ACR70\] responders per treatment arm) / (total number of participants per treatment arm) \* 100.

    Time frame: Week 12

  8. Percentage of Participants With of ACR20/50/70 Response - Part B

    ACR20 (or ACR50 or ACR70) responders were participants with at least 20% (or 50% or 70% respectively) improvement from baseline TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants was calculated as: (number of ACR20 \[or ACR50 or ACR70\] responders per treatment arm) / (total number of participants per treatment arm) \* 100\].

    Time frame: Week 64

  9. Change From Baseline in Individual Components of the ACR Core Set-TJC - Part A

    TJC was determined by examination of 28 joint counts that were assessed for tenderness by pressure and joint manipulation on physical examination. The participant was asked for pain sensations on these manipulations and was watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-non-tender dichotomy. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, arthrodesed joints were identified by the investigator and excluded from evaluation during the study. Any joints that required intra-articular injections during the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of tender joints ranged from 0-28. A negative change indicated fewer tender joints.

    Time frame: Baseline, up to Week 12

  10. Change From Baseline in Individual Components of the ACR Core Set-TJC - Part B

    TJC was determined by examination of 28 joint counts that were assessed for tenderness by pressure and joint manipulation on physical examination. The participant was asked for pain sensations on these manipulations and was watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-non-tender dichotomy. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, arthrodesed joints were identified by the investigator and excluded from evaluation during the study. Any joints that required intra-articular injections during the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of tender joints ranged from 0-28. A negative change indicated fewer tender joints.

    Time frame: Baseline, Week 64

  11. Change From Baseline in Individual Components of the ACR Core Set-SJC - Part A

    SJC was determined by examination of 28 joint that were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. Swelling secondary to osteoarthrosis was assessed as not swollen, unless there was unmistakable fluctuation. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, or arthrodesed joints were identified by the investigator and were excluded from evaluation during the study. Any joints that required intra-articular injections over the course of the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of swollen joints count ranged from 0-28. A negative change indicated fewer swollen joints.

    Time frame: Baseline, up to Week 12

  12. Change From Baseline in Individual Components of the ACR Core Set-SJC - Part B

    SJC was determined by examination of 28 joint that were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. Swelling secondary to osteoarthrosis was assessed as not swollen, unless there was unmistakable fluctuation. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, or arthrodesed joints were identified by the investigator and were excluded from evaluation during the study. Any joints that required intra-articular injections over the course of the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of swollen joints ranged from 0-28. A negative change indicated fewer swollen joints.

    Time frame: Baseline, Week 64

  13. Change From Baseline in Individual Components of the ACR Core Set-PAAP VAS - Part A

    Participants were asked to assess his/her current level of arthritis pain by marking a vertical tick on a 100-mm horizontal VAS with the left end (0 mm) marked as "no pain" and the right end (100 mm) marked "worst possible pain." The scale was administered prior to the TJC and SJC count examinations. Results were expressed in mm measured between the left end of the scale and the crossing point of the vertical line of the tick. A negative change indicated a lessening of the participant's arthritis pain.

    Time frame: Baseline, up to Week 12

  14. Change From Baseline in Individual Components of the ACR Core Set-PAAP-VAS - Part B

    Participants were asked to assess his/her current level of arthritis pain by marking a vertical tick on a 100-mm horizontal VAS with the left end (0 mm) marked as "no pain" and the right end (100 mm) marked "worst possible pain". The scale was administered prior to the TJC and SJC count examinations. Results were expressed in mm measured between the left end of the scale and the crossing point of the vertical line of the tick. A negative change indicated a lessening of the participant's arthritis pain.

    Time frame: Baseline, Week 64

  15. Change From Baseline in Individual Components of the ACR Core Set - PtGADA-VAS - Part A

    The participant was asked to give an overall assessment of his/her current arthritis disease activity. The participants response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as "no arthritis activity" to the right end (100 mm) marked "extremely active arthritis." A negative change indicated an improvement in the participant's assessment of disease activity.

    Time frame: Baseline, up to Week 12

  16. Change From Baseline in Individual Components of the ACR Core Set - PtGADA-VAS - Part B

    The participant was asked to give an overall assessment of his/her current arthritis disease activity. The participants response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as "no arthritis activity" to the right end (100 mm) marked "extremely active arthritis." A negative change indicated an improvement in the participant's assessment of disease activity.

    Time frame: Baseline, Week 64

  17. Change From Baseline in Individual Components of the ACR Core Set - PhGA-VAS - Part A

    The investigator gave an overall assessment of the severity of the participants disease activity. The physician's response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as "no arthritis activity" and the right end (100 mm) marked as "extremely active arthritis." A negative change indicated a lessening in the severity of the participant's disease activity.

    Time frame: Baseline, up to Week 12

  18. Change From Baseline in Individual Components of the ACR Core Set - PhGA-VAS - Part B

    The investigator gave an overall assessment of the severity of the participant's disease activity. The physician's response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as "no arthritis activity" and the right end (100 mm) marked as "extremely active arthritis." A negative change indicated a lessening in the severity of the participant's disease activity.

    Time frame: Baseline, Week 64

  19. Change From Baseline in Individual Components of the ACR Core Set - CRP - Part A

    CRP is a biological marker of disease activity. A negative change indicated an improvement in participant's disease activity.

    Time frame: Baseline, up to Week 12

  20. Change From Baseline in Individual Components of the ACR Core Set - CRP - Part B

    CRP is a biological marker of disease activity. A negative change indicated an improvement in participant's disease activity.

    Time frame: Baseline, Week 64

  21. Percentage of Participants in European League Against Rheumatism Responder Index (EULAR) 28 - Part A

    Assessment of participant's rheumatoid arthritis (RA) by the EULAR that is based on the DAS 28 joint count. Participants were categorized as non-responders or responders (moderate responders + good responders). Percentage of participants was calculated as: (number of responders / number of participants) \* 100.

    Time frame: Week 12

  22. Percentage of Participants in EULAR28 - Part B

    Assessment of participant's RA by the EULAR that is based on the DAS28 joint count. Participants were categorized as non-responders or responders (moderate responders + good responders). Percentage of participants was calculated as: (number of responders / number of participants) \* 100.

    Time frame: Week 64

  23. ACR-N - Part A

    ACR-N was a continuous measure of clinical, laboratory and functional outcomes in RA that characterized the percentage of improvement in RA disease activity from baseline. The index was defined as the lowest of either: the percent change in TJC, the percent change in SJC, or the median percent change of the remaining 5 ACR core criteria: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. For each criterion, percent change was calculated as: \[(post baseline value - baseline value) / baseline value\] \* 100.

    Time frame: Week 12

  24. ACR-N - Part B

    ACR-N was a continuous measure of clinical, laboratory and functional outcomes in RA that characterized the percentage of improvement in RA disease activity from baseline. The index was defined as the lowest of either: the percent change in TJC, the percent change in SJC, or the median percent change of the remaining 5 ACR core criteria: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. For each criterion, percent change was calculated as: \[(post baseline value - baseline value)/baseline value\] \* 100.

    Time frame: Week 64

  25. Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale - Part A

    The FACIT Fatigue Scale was a brief participant-reported questionnaire measure of fatigue and consisted of 13 items that assessed tiredness, weakness and difficulty conducting usual activities due to fatigue. Each question was scored on a 5-point scale from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue. For missing data, scores were prorated using the average of the other answers in the scales as long as more than 50% of the items were answered. A negative change indicated less fatigue.

    Time frame: Baseline, up to Week 12

  26. Change From Baseline in FACIT Fatigue Scale - Part B

    The FACIT-Fatigue Scale was a brief participant-reported questionnaire measure of fatigue and consisted of 13 items that assessed tiredness, weakness and difficulty conducting usual activities due to fatigue. Each question was scored on a 5-point scale from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue. For missing data, scores were prorated using the average of the other answers in the scales as long as more than 50% of the items were answered. A negative change indicated less fatigue.

    Time frame: Baseline, Week 64

  27. Change From Baseline in Duration of Morning Stiffness (Minutes) - Part A

    The investigator queried the participants about the duration of morning stiffness in and around their joints and the results (in minutes) were recorded by the investigator. Duration was the time from when the participants woke up to when normal activities could be resumed. Durations recorded as longer than 12 hours (720 minutes) were summarized as 720 minutes. An increase in duration from baseline indicated a joint worsening and a decrease from baseline indicated joint improvement.

    Time frame: Baseline, up to Week 12

  28. Change From Baseline in Duration of Morning Stiffness (Minutes) - Part B

    The investigator queried the participants about the duration of morning stiffness in and around their joints and the results (in minutes) were recorded by the investigator. Duration was the time from when the participants woke up to when normal activities could be resumed. Durations recorded as longer than 12 hours (720 minutes) were summarized as 720 minutes. An increase in duration from baseline indicated a joint worsening and a decrease from baseline indicated joint improvement.

    Time frame: Baseline, Week 64

  29. Change From Baseline in HAQ-DI - Part A

    HAQ-DI was a participant-reported questionnaire that consisted of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 disability domains were required to compute the participant's HAQ-DI score. If the participant had scores for fewer than 6 categories, the HAQ-DI score was considered missing. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, with a possible scores range of 0 to 3. Negative mean changes from baseline indicated improvement.

    Time frame: Baseline, up to Week 12

  30. Change From Baseline in HAQ-DI - Part B

    HAQ-DI was a participant-reported questionnaire that consisted of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 disability domains were required to compute the participant's HAQ-DI score. If the participant had scores for fewer than 6 categories, the HAQ-DI score was considered missing. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3. Negative mean changes from baseline indicated improvement.

    Time frame: Baseline, Week 64

  31. Relationship Between Exposure and Response of Individual Components of the ACR Core Set

    Time frame: Through Week 72

  32. Relationship Between Exposure and Response of ACR20/50/70/N

    Time frame: Through Week 72

  33. Relationship Between Exposure and Response of DAS28

    Time frame: Through Week 72

  34. Relationship Between Exposure and Response of EULAR28

    Time frame: Through Week 72

  35. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2439821 at Steady State

    Evaluable PK concentrations from all time points, including data from placebo participants who elected active treatment in Part B, were combined and utilized in a population approach to determine the population median estimates and 90% confidence intervals at steady state. Day 0 and Week 6 postdose samples were collected as late as possible during the dosing visit (in other words, the postdose samples were collected at the end of their respective visits).

    Time frame: Predose: Day 0, Day 1 or 2 or 3, Day 7, Weeks 6, 10, 16, 40 and 64 and Postdose: Day 0 and Week 6

  36. Percentage of Participants With Anti-LY2439821 Antibodies

    Treatment-emergent anti-LY2439821 antibody positive participants were defined as a titer change from baseline that was at least 2 dilutions (4-fold) increase. Participants must have had an assessment to be classified as treatment emergent antibody positive or negative.

    Time frame: Week 16, Week 64

07

Results

Posted May 26, 2016

Participant flow

Part A
Participant flow — Part A
MilestonePlacebo [bDMARD-naive Population]3 mg LY2439821 [bDMARD-naive Population]10 mg LY2439821 [bDMARD-naive Population]30 mg LY2439821 [bDMARD-naive Population]80 mg LY2439821 [bDMARD-naive Population]180 mg LY2439821[bDMARD-naive Population]Placebo [TNFα-IR Population]80 mg LY2439821 [TNFα-IR Population]180 mg LY2439821 [TNFα-IR Population]
Started544035375737646559
Received ≥1 doses of study drug544035375737646559
Completed483633345233525851
Not completed6423541278
Withdrew: Adverse event210101033
Withdrew: Entry criteria000002000
Withdrew: Lack of efficacy010000400
Withdrew: Lost to follow-up200001000
Withdrew: Parent/caregiver decision000100000
Withdrew: Physician decision000010102
Withdrew: Sponsor decision001010021
Withdrew: Withdrawal by subject221130511
Withdrew: Protocol violation000000211
Part B
Participant flow — Part B
MilestonePlacebo [bDMARD-naive Population]3 mg LY2439821 [bDMARD-naive Population]10 mg LY2439821 [bDMARD-naive Population]30 mg LY2439821 [bDMARD-naive Population]80 mg LY2439821 [bDMARD-naive Population]180 mg LY2439821[bDMARD-naive Population]Placebo [TNFα-IR Population]80 mg LY2439821 [TNFα-IR Population]180 mg LY2439821 [TNFα-IR Population]
Started463633345132515750
Completed413327314426293832
Not completed536376221918
Withdrew: Adverse event011010522
Withdrew: Death001000010
Withdrew: Lack of efficacy2111231296
Withdrew: Lost to follow-up000100001
Withdrew: Physician decision001021002
Withdrew: Sponsor decision100001021
Withdrew: Withdrawal by subject212121455
Withdrew: Entry criteria000000101

Outcome measures

PrimaryDose-Response Relationship Measured by the Percentage of Participants With American College of Rheumatology (ACR) 20 Response in bDMARD-Naive Population

ACR20 responders are participants with at least 20% improvement from baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: Health Assessment Questionnaire-Disability Index (HAQ-DI) which measured participants perceived degree of difficulty performing daily activities, C-reactive Protein (CRP), Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), Patient's Global Assessment of Disease Activity-VAS(PtGADA-VAS), and Physician's Global Assessment of Disease Activity-VAS (PhGA-VAS). Missing values were imputed using Non-Responder Imputation (NRI). Percentage of participants achieving ACR20 response was calculated as: (number of ACR20 responders / number of participants treated) \* 100.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Dose-Response Relationship Measured by the Percentage of Participants With American College of Rheumatology (ACR) 20 Response in bDMARD-Naive Population
percentage of participantsPlacebo (bDMARD-naive Population)3 mg LY2439821 (bDMARD-naive Population)10 mg LY2439821 (bDMARD-naive Population)30 mg LY2439821 (bDMARD-naive Population)80 mg LY2439821 (bDMARD-naive Population)180 mg LY2439821 (bDMARD-naive Population)
Dose-Response Relationship Measured by the Percentage of Participants With American College of Rheumatology (ACR) 20 Response in bDMARD-Naive Population34.146.252.255.055.354.0
Statistical analysis
  • Placebo (bDMARD-naive Population) vs 3 mg LY2439821 (bDMARD-naive Population) vs 10 mg LY2439821 (bDMARD-naive Population) vs 30 mg LY2439821 (bDMARD-naive Population) vs 80 mg LY2439821 (bDMARD-naive Population) vs 180 mg LY2439821 (bDMARD-naive Population) · Regression, Logistic · p = 0.031 (A log transformed dose was used in the model.)
SecondaryPercentage of Participants With ACR20 Response in Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR) Population

ACR20 responders were participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants achieving ACR20 response was calculated as: (number of ACR20 responders / number of participants treated) \* 100.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With ACR20 Response in Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR) Population
percentage of participantsPlacebo (TNFα-IR Population)80 mg LY2439821 (TNFα-IR Population)180 mg LY2439821 (TNFα-IR Population)
Percentage of Participants With ACR20 Response in Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR) Population23.440.039.0
Statistical analysis
  • Placebo (TNFα-IR Population) vs 80 mg LY2439821 (TNFα-IR Population) · Fisher Exact · p = 0.033
  • Placebo (TNFα-IR Population) vs 180 mg LY2439821 (TNFα-IR Population) · Fisher Exact · p = 0.047
SecondarySmallest Doses That Achieve 10%, 50%, and 90% of the Maximum ACR 20 Response in bDMARD-Naive Population

ACR20 responders are participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. The model used in the dose response analysis was used to estimate the doses that achieved 10%, 50%, and 90% of the maximal drug efficacy. Missing values were imputed using NRI. The log transformed dose was evaluated.

Time frame:
Week 12
Reported as:
Number · log (dose) mg
Smallest Doses That Achieve 10%, 50%, and 90% of the Maximum ACR 20 Response in bDMARD-Naive Population
log (dose) mg3 mg to 180 mg LY2439821 (bDMARD-naive Population)
Estimated dose to achieve 10% response0.8
Estimated dose to achieve 50% response2.4
Estimated dose to achieve 90% response13.8
SecondarySmallest Doses That Achieved 10%, 50%, and 90% of the Maximum Disease Activity Score (DAS) 28 Response in bDMARD-Naive Population

DAS modified included the 28 diarthrodial joint count (DAS28) that consisted of a composite score of the following variables: TJC out of 28 (TJC28), SJC out of 28 (SJC28), CRP \[milligrams per liter (mg/L)\], and PtGADA on a 0 to 100 millimeter (mm) VAS ranging from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 was calculated as: DAS28 - CRP = 0.56(square root of TJC28) + 0.28(square root of SJC28) + 0.36(ln\[CRP +1\]) + 0.014(VAS) + 0.96.

Time frame:
Week 12
Reported as:
Number · log (dose) mg
Smallest Doses That Achieved 10%, 50%, and 90% of the Maximum Disease Activity Score (DAS) 28 Response in bDMARD-Naive Population
log (dose) mg3 mg to 180 mg (bDMARD-naive Population)
Estimated dose to achieve 10% response7.3
Estimated dose to achieve 50 % response41.5
Estimated dose to achieve 90% response97.0
SecondarySmallest Doses That Achieve 10%, 50%, and 90% of the Maximum ACR50 Response in bDMARD-Naive Population

ACR50 responders were participants with at least 50% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI.

Time frame:
Week 12
Reported as:
Number · log (dose) mg
Smallest Doses That Achieve 10%, 50%, and 90% of the Maximum ACR50 Response in bDMARD-Naive Population
log (dose) mg3 mg to 180 mg LY2439821 (bDMARD-naive Population)
Estimated dose to achieve 10% response7.3
Estimated dose to achieve 50% response37.9
Estimated dose to achieve 90% response81.2
SecondaryChange From Baseline in Disease Activity Score (DAS28)-Part A

DAS28 consisted of a composite score of the following variables: TJC28, SJC28, CRP, and PtGADA-VAS. DAS28 was calculated as: DAS28 - CRP =0.56(square root TJC28) + 0.28(square root SJC28) + 0.36(ln\[CRP +1\]) + 0.014(VAS) + 0.96. A negative change indicated an improvement.

Time frame:
Baseline, up to Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Score (DAS28)-Part A
units on a scalePlacebo (bDMARD-naive Population)3 mg LY2439821 (bDMARD-naive Population)10 mg LY2439821 (bDMARD-naive Population)30 mg LY2439821 (bDMARD-naive Population)80 mg LY2439821 (bDMARD-naive Population)180 mg LY2439821 (bDMARD-naive Population)Placebo (TNFα-IR Population)80 mg LY2439821 (TNFα-IR Population)180 mg LY2439821 (TNFα-IR Population)
Change From Baseline in Disease Activity Score (DAS28)-Part A-0.818 ± 0.981-1.308 ± 1.092-1.565 ± 1.440-1.671 ± 1.193-1.686 ± 1.344-1.940 ± 1.152-0.619 ± 1.109-1.310 ± 1.303-1.571 ± 1.261
Statistical analysis
  • Placebo (bDMARD-naive Population) vs 3 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.013 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 10 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.004 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 30 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = <0.001 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 80 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = <0.001 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 180 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = <0.001 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (TNFα-IR Population) vs 80 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = <0.001 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (TNFα-IR Population) vs 180 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = <0.001 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
SecondaryChange From Baseline in DAS28 - Part B

DAS28 consisted of a composite score of the following variables: TJC28, SJC28, CRP, and PtGADA-VAS. DAS28 was calculated as: DAS28 - CRP =0.56(square root TJC28) + 0.28(square root SJC28) + 0.36(ln\[CRP +1\]) + 0.014(VAS) + 0.96. A negative change indicated an improvement.

Time frame:
Baseline, Week 64
Reported as:
Mean · units on a scale
Change From Baseline in DAS28 - Part B
units on a scalePlacebo/160 mg LY2439821 (bDMARD-naive Population)3 mg/160 mg LY2439821(bDMARD-naive Population)10 mg/160 mg LY2439821(bDMARD-naive Population)30 mg/160 mg LY2439821(bDMARD-naive Population)80 mg/160 mg LY2439821(bDMARD-naive Population)180 mg/160 mg LY2439821 (bDMARD-naive Population)Placebo/160 mg LY2439821(TNFα-IR Population)80 mg/160 mg LY2439821(TNFα-IR Population)180 mg/160 mg LY2439821(TNFα-IR Population)
Change From Baseline in DAS28 - Part B-2.143 ± 1.177-1.832 ± 1.031-2.320 ± 1.292-2.277 ± 1.337-2.280 ± 1.316-2.475 ± 1.140-1.740 ± 1.460-1.604 ± 1.282-1.874 ± 1.279
SecondaryPercentage of Participants With ACR20/50/70 Response - Part A

ACR20 (or ACR50 or ACR70) responders were participants with at least 20% (or 50% or 70%, respectively) improvement from baseline TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants was calculated as: (number of ACR20 \[or ACR50 or ACR70\] responders per treatment arm) / (total number of participants per treatment arm) \* 100.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With ACR20/50/70 Response - Part A
percentage of participantsPlacebo (bDMARD-naive Population)3 mg LY2439821 (bDMARD-naive Population)10 mg LY2439821 (bDMARD-naive Population)30 mg LY2439821 (bDMARD-naive Population)80 mg LY2439821 (bDMARD-naive Population)180 mg LY2439821 (bDMARD-naive Population)Placebo (TNFα-IR Population)80 mg LY2439821 (TNFα-IR Population)180 mg LY2439821 (TNFα-IR Population)
ACR2035.245.042.970.350.954.123.440.039.0
ACR509.317.528.629.726.327.07.820.016.9
ACR701.95.014.313.57.013.53.13.110.2
Statistical analysis
  • Placebo (bDMARD-naive Population) vs 3 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.227 (P-value is for ACR20-NRI at Week 12.)
  • Placebo (bDMARD-naive Population) vs 10 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.306 (P-value is for ACR20-NRI at Week 12.)
  • Placebo (bDMARD-naive Population) vs 30 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.001 (P-value is for ACR20-NRI at Week 12.)
  • Placebo (bDMARD-naive Population) vs 80 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.070 (P-value is for ACR20-NRI at Week 12.)
  • Placebo (bDMARD-naive Population) vs 180 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.058 (P-value is for ACR20-NRI at Week 12.)
  • Placebo (TNFα-IR Population) vs 80 mg LY2439821 (TNFα-IR Population) · Fisher Exact · p = 0.033 (P-value is for ACR20-NRI at Week 12.)
  • Placebo (TNFα-IR Population) vs 180 mg LY2439821 (TNFα-IR Population) · Fisher Exact · p = 0.047 (P-value is for ACR20-NRI at Week 12.)
  • Placebo (bDMARD-naive Population) vs 3 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.191 (P-value is for ACR50-NRI at Week 12.)
  • Placebo (bDMARD-naive Population) vs 10 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.019 (P-value is for ACR50-NRI at Week 12.)
  • Placebo (bDMARD-naive Population) vs 30 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.013 (P-value is for ACR50-NRI at Week 12.)
  • Placebo (bDMARD-naive Population) vs 80 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.017 (P-value is for ACR50-NRI at Week 12.)
  • Placebo (bDMARD-naive Population) vs 180 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.026 (P-value is for ACR50-NRI at Week 12.)
  • Placebo (TNFα-IR Population) vs 80 mg LY2439821 (TNFα-IR Population) · Fisher Exact · p = 0.039 (P-value is for ACR50-NRI at Week 12.)
  • Placebo (TNFα-IR Population) vs 180 mg LY2439821 (TNFα-IR Population) · Fisher Exact · p = 0.102 (P-value is for ACR50-NRI at Week 12.)
  • Placebo (bDMARD-naive Population) vs 3 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.388 (P-value is for ACR70-NRI at Week 12.)
  • Placebo (bDMARD-naive Population) vs 10 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.033 (P-value is for ACR70-NRI at Week 12.)
  • Placebo (bDMARD-naive Population) vs 30 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.039 (P-value is for ACR70-NRI at Week 12.)
  • Placebo (bDMARD-naive Population) vs 80 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.199 (P-value is for ACR70-NRI at Week 12.)
  • Placebo (bDMARD-naive Population) vs 180 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.039 (P-value is for ACR70-NRI at Week 12.)
  • Placebo (TNFα-IR Population) vs 80 mg LY2439821 (TNFα-IR Population) · Fisher Exact · p = 0.696 (P-value is for ACR70-NRI at Week 12.)
  • Placebo (TNFα-IR Population) vs 180 mg LY2439821 (TNFα-IR Population) · Fisher Exact · p = 0.112 (P-value is for ACR70-NRI at Week 12.)
SecondaryPercentage of Participants With of ACR20/50/70 Response - Part B

ACR20 (or ACR50 or ACR70) responders were participants with at least 20% (or 50% or 70% respectively) improvement from baseline TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants was calculated as: (number of ACR20 \[or ACR50 or ACR70\] responders per treatment arm) / (total number of participants per treatment arm) \* 100\].

Time frame:
Week 64
Reported as:
Number · percentage of participants
Percentage of Participants With of ACR20/50/70 Response - Part B
percentage of participantsPlacebo/160 mg LY2439821(bDMARD-naive Population)3 mg/160 mg LY2439821 (bDMARD-naive Population)10 mg/160 mg LY2439821 (bDMARD-naive Population)30 mg/160 mg LY2439821 (bDMARD-naive Population)80 mg/160 mg LY2439821 (bDMARD-naive Population)180 mg/160 mg LY2439821 (bDMARD-naive Population)Placebo/160 mg LY2439821(TNFα-IR Population)80 mg/160 mg LY2439821 (TNFα-IR Population)180 mg/160 mg LY2439821 (TNFα-IR Population)
ACR2075.065.667.980.672.780.851.643.964.7
ACR5042.537.550.048.447.761.532.322.038.2
ACR7017.512.532.122.611.430.819.49.817.6
SecondaryChange From Baseline in Individual Components of the ACR Core Set-TJC - Part A

TJC was determined by examination of 28 joint counts that were assessed for tenderness by pressure and joint manipulation on physical examination. The participant was asked for pain sensations on these manipulations and was watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-non-tender dichotomy. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, arthrodesed joints were identified by the investigator and excluded from evaluation during the study. Any joints that required intra-articular injections during the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of tender joints ranged from 0-28. A negative change indicated fewer tender joints.

Time frame:
Baseline, up to Week 12
Reported as:
Mean · tender joints
Change From Baseline in Individual Components of the ACR Core Set-TJC - Part A
tender jointsPlacebo (bDMARD-naive Population)3 mg LY2439821 (bDMARD-naive Population)10 mg LY2439821 (bDMARD-naive Population)30 mg LY2439821 (bDMARD-naive Population)80 mg LY2439821 (bDMARD-naive Population)180 mg LY2439821 (bDMARD-naive Population)Placebo (TNFα-IR Population)80 mg LY2439821 (TNFα-IR Population)180 mg LY2439821 (TNFα-IR Population)
Change From Baseline in Individual Components of the ACR Core Set-TJC - Part A-2.95 ± 5.20-6.02 ± 7.35-6.79 ± 7.67-7.05 ± 6.28-7.66 ± 8.96-8.96 ± 7.47-2.96 ± 6.31-6.02 ± 7.31-6.02 ± 6.74
Statistical analysis
  • Placebo (bDMARD-naive Population) vs 3 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.017 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 10 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.042 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 30 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.004 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 80 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = <0.001 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 180 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = <0.001 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (TNFα-IR Population) vs 80 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = 0.008 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (TNFα-IR Population) vs 180 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = 0.007 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
SecondaryChange From Baseline in Individual Components of the ACR Core Set-TJC - Part B

TJC was determined by examination of 28 joint counts that were assessed for tenderness by pressure and joint manipulation on physical examination. The participant was asked for pain sensations on these manipulations and was watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-non-tender dichotomy. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, arthrodesed joints were identified by the investigator and excluded from evaluation during the study. Any joints that required intra-articular injections during the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of tender joints ranged from 0-28. A negative change indicated fewer tender joints.

Time frame:
Baseline, Week 64
Reported as:
Mean · tender joints
Change From Baseline in Individual Components of the ACR Core Set-TJC - Part B
tender jointsPlacebo/160 mg LY2439821(bDMARD-naive Population)3 mg/160 mg LY2439821 (bDMARD-naive Population)10 mg/160 mg LY2439821 (bDMARD-naive Population)30 mg/160 mg LY2439821 (bDMARD-naive Population)80 mg/160 mg LY2439821 (bDMARD-naive Population)180 mg/160 mg LY2439821 (bDMARD-naive Population)Placebo/160 mg LY2439821(TNFα-IR Population)80 mg/160 mg LY2439821 (TNFα-IR Population)180 mg/160 mg LY2439821 (TNFα-IR Population)
Change From Baseline in Individual Components of the ACR Core Set-TJC - Part B-8.73 ± 6.85-8.78 ± 5.32-11.43 ± 6.54-9.55 ± 6.20-10.86 ± 7.48-10.55 ± 7.11-6.62 ± 8.39-7.35 ± 6.83-6.81 ± 6.11
SecondaryChange From Baseline in Individual Components of the ACR Core Set-SJC - Part A

SJC was determined by examination of 28 joint that were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. Swelling secondary to osteoarthrosis was assessed as not swollen, unless there was unmistakable fluctuation. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, or arthrodesed joints were identified by the investigator and were excluded from evaluation during the study. Any joints that required intra-articular injections over the course of the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of swollen joints count ranged from 0-28. A negative change indicated fewer swollen joints.

Time frame:
Baseline, up to Week 12
Reported as:
Mean · swollen joints
Change From Baseline in Individual Components of the ACR Core Set-SJC - Part A
swollen jointsPlacebo (bDMARD-naive Population)3 mg LY2439821 (bDMARD-naive Population)10 mg LY2439821 (bDMARD-naive Population)30 mg LY2439821 (bDMARD-naive Population)80 mg LY2439821 (bDMARD-naive Population)180 mg LY2439821 (bDMARD-naive Population)Placebo (TNFα-IR Population)80 mg LY2439821 (TNFα-IR Population)180 mg LY2439821 (TNFα-IR Population)
Change From Baseline in Individual Components of the ACR Core Set-SJC - Part A-2.69 ± 6.07-4.25 ± 5.58-6.51 ± 7.65-6.16 ± 6.44-7.49 ± 7.98-6.52 ± 6.62-1.69 ± 5.93-5.57 ± 5.51-5.15 ± 5.65
Statistical analysis
  • Placebo (bDMARD-naive Population) vs 3 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.093 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 10 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.023 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 30 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.006 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 80 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.001 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 180 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.028 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (TNFα-IR Population) vs 80 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = <0.001 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (TNFα-IR Population) vs 180 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = <0.001 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
SecondaryChange From Baseline in Individual Components of the ACR Core Set-SJC - Part B

SJC was determined by examination of 28 joint that were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. Swelling secondary to osteoarthrosis was assessed as not swollen, unless there was unmistakable fluctuation. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, or arthrodesed joints were identified by the investigator and were excluded from evaluation during the study. Any joints that required intra-articular injections over the course of the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of swollen joints ranged from 0-28. A negative change indicated fewer swollen joints.

Time frame:
Baseline, Week 64
Reported as:
Mean · swollen joints
Change From Baseline in Individual Components of the ACR Core Set-SJC - Part B
swollen jointsPlacebo/160 mg LY2439821(bDMARD-naive Population)3 mg/160 mg LY2439821 (bDMARD-naive Population)10 mg/160 mg LY2439821 (bDMARD-naive Population)30 mg/160 mg LY2439821 (bDMARD-naive Population)80 mg/160 mg LY2439821 (bDMARD-naive Population)180 mg/160 mg LY2439821 (bDMARD-naive Population)Placebo/160 mg LY2439821(TNFα-IR Population)80 mg/160 mg LY2439821 (TNFα-IR Population)180 mg/160 mg LY2439821 (TNFα-IR Population)
Change From Baseline in Individual Components of the ACR Core Set-SJC - Part B-7.25 ± 6.15-5.73 ± 4.95-9.06 ± 5.92-7.26 ± 5.73-8.95 ± 6.64-8.96 ± 6.06-7.32 ± 6.45-5.46 ± 6.51-6.29 ± 5.75
SecondaryChange From Baseline in Individual Components of the ACR Core Set-PAAP VAS - Part A

Participants were asked to assess his/her current level of arthritis pain by marking a vertical tick on a 100-mm horizontal VAS with the left end (0 mm) marked as "no pain" and the right end (100 mm) marked "worst possible pain." The scale was administered prior to the TJC and SJC count examinations. Results were expressed in mm measured between the left end of the scale and the crossing point of the vertical line of the tick. A negative change indicated a lessening of the participant's arthritis pain.

Time frame:
Baseline, up to Week 12
Reported as:
Mean · mm
Change From Baseline in Individual Components of the ACR Core Set-PAAP VAS - Part A
mmPlacebo (bDMARD-naive Population)3 mg LY2439821 (bDMARD-naive Population)10 mg LY2439821 (bDMARD-naive Population)30 mg LY2439821 (bDMARD-naive Population)80 mg LY2439821 (bDMARD-naive Population)180 mg LY2439821 (bDMARD-naive Population)Placebo (TNFα-IR Population)80 mg LY2439821 (TNFα-IR Population)180 mg LY2439821 (TNFα-IR Population)
Change From Baseline in Individual Components of the ACR Core Set-PAAP VAS - Part A-14.8 ± 23.7-18.7 ± 22.8-21.3 ± 28.4-29.8 ± 24.1-25.8 ± 23.0-25.3 ± 27.5-9.4 ± 24.0-10.3 ± 24.7-18.8 ± 26.6
Statistical analysis
  • Placebo (bDMARD-naive Population) vs 3 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.247 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 10 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.315 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 30 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.006 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 80 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.042 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 180 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.055 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (TNFα-IR Population) vs 80 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = 0.365 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (TNFα-IR Population) vs 180 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = 0.005 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
SecondaryChange From Baseline in Individual Components of the ACR Core Set-PAAP-VAS - Part B

Participants were asked to assess his/her current level of arthritis pain by marking a vertical tick on a 100-mm horizontal VAS with the left end (0 mm) marked as "no pain" and the right end (100 mm) marked "worst possible pain". The scale was administered prior to the TJC and SJC count examinations. Results were expressed in mm measured between the left end of the scale and the crossing point of the vertical line of the tick. A negative change indicated a lessening of the participant's arthritis pain.

Time frame:
Baseline, Week 64
Reported as:
Mean · mm
Change From Baseline in Individual Components of the ACR Core Set-PAAP-VAS - Part B
mmPlacebo/160 mg LY2439821 (bDMARD-naive Population)3 mg/160 mg LY2439821 (bDMARD-naive Population)10 mg/160 mg LY2439821 (bDMARD-naive Population)30 mg/160 mg LY2439821 (bDMARD-naive Population)80 mg/160 mg LY2439821 (bDMARD-naive Population)180 mg/160 mg LY2439821 (bDMARD-naive Population)Placebo/160 mg LY2439821 (TNFα-IR Population)80 mg/160 mg LY2439821 (TNFα-IR Population)180 mg/160 mg LY2439821 (TNFα-IR Population)
Change From Baseline in Individual Components of the ACR Core Set-PAAP-VAS - Part B-32.5 ± 27.8-26.2 ± 20.3-33.3 ± 33.4-36.2 ± 27.4-32.4 ± 22.6-41.2 ± 23.0-25.5 ± 22.3-16.5 ± 21.1-26.2 ± 26.2
SecondaryChange From Baseline in Individual Components of the ACR Core Set - PtGADA-VAS - Part A

The participant was asked to give an overall assessment of his/her current arthritis disease activity. The participants response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as "no arthritis activity" to the right end (100 mm) marked "extremely active arthritis." A negative change indicated an improvement in the participant's assessment of disease activity.

Time frame:
Baseline, up to Week 12
Reported as:
Mean · mm
Change From Baseline in Individual Components of the ACR Core Set - PtGADA-VAS - Part A
mmPlacebo (bDMARD-naive Population)3 mg LY2439821 (bDMARD-naive Population)10 mg LY2439821 (bDMARD-naive Population)30 mg LY2439821 (bDMARD-naive Population)80 mg LY2439821 (bDMARD-naive Population)180 mg LY2439821 (bDMARD-naive Population)Placebo (TNFα-IR Population)80 mg LY2439821 (TNFα-IR Population)180 mg LY2439821 (TNFα-IR Population)
Change From Baseline in Individual Components of the ACR Core Set - PtGADA-VAS - Part A-19.2 ± 21.4-17.3 ± 20.9-18.5 ± 28.7-29.1 ± 23.1-22.1 ± 23.7-30.1 ± 26.9-10.1 ± 24.7-12.1 ± 27.9-21.6 ± 25.4
Statistical analysis
  • Placebo (bDMARD-naive Population) vs 3 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.778 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 10 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.865 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 30 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.030 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 80 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.331 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 180 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.039 (P-value is for Week 12..)ANCOVA adjusted for treatment and baseline value.
  • Placebo (TNFα-IR Population) vs 80 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = 0.292 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (TNFα-IR Population) vs 180 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = 0.003 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
SecondaryChange From Baseline in Individual Components of the ACR Core Set - PtGADA-VAS - Part B

The participant was asked to give an overall assessment of his/her current arthritis disease activity. The participants response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as "no arthritis activity" to the right end (100 mm) marked "extremely active arthritis." A negative change indicated an improvement in the participant's assessment of disease activity.

Time frame:
Baseline, Week 64
Reported as:
Mean · mm
Change From Baseline in Individual Components of the ACR Core Set - PtGADA-VAS - Part B
mmPlacebo/160 mg LY2439821 (bDMARD-naive Population)3 mg/160 mg LY2439821 (bDMARD-naive Population)10 mg/160 mg LY2439821 (bDMARD-naive Population)30 mg/160 mg LY2439821 (bDMARD-naive Population)80 mg/160 mg LY2439821 (bDMARD-naive Population)180 mg/160 mg LY2439821 (bDMARD-naive Population)Placebo/160 mg LY2439821 (TNFα-IR Population)80 mg/160 mg LY2439821 (TNFα-IR Population)180 mg/160 mg LY2439821 (TNFα-IR Population)
Change From Baseline in Individual Components of the ACR Core Set - PtGADA-VAS - Part B-35.4 ± 26.2-24.9 ± 25.4-31.8 ± 30.4-34.8 ± 27.0-28.5 ± 24.7-39.8 ± 25.5-22.4 ± 23.2-17.8 ± 21.4-25.1 ± 23.9
SecondaryChange From Baseline in Individual Components of the ACR Core Set - PhGA-VAS - Part A

The investigator gave an overall assessment of the severity of the participants disease activity. The physician's response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as "no arthritis activity" and the right end (100 mm) marked as "extremely active arthritis." A negative change indicated a lessening in the severity of the participant's disease activity.

Time frame:
Baseline, up to Week 12
Reported as:
Mean · mm
Change From Baseline in Individual Components of the ACR Core Set - PhGA-VAS - Part A
mmPlacebo (bDMARD-naive Population)3 mg LY2439821 (bDMARD-naive Population)10 mg LY2439821 (bDMARD-naive Population)30 mg LY2439821 (bDMARD-naive Population)80 mg LY2439821 (bDMARD-naive Population)180 mg LY2439821 (bDMARD-naive Population)Placebo (TNFα-IR Population)80 mg LY2439821 (TNFα-IR Population)180 mg LY2439821 (TNFα-IR Population)
Change From Baseline in Individual Components of the ACR Core Set - PhGA-VAS - Part A-16.0 ± 19.0-21.0 ± 15.6-21.7 ± 25.2-26.7 ± 18.1-24.5 ± 22.3-28.8 ± 24.2-8.6 ± 21.4-25.7 ± 22.2-22.0 ± 24.0
Statistical analysis
  • Placebo (bDMARD-naive Population) vs 3 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.090 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 10 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.131 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 30 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.008 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 80 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.013 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 180 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.010 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (TNFα-IR Population) vs 80 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = <0.001 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (TNFα-IR Population) vs 180 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = <0.001 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
SecondaryChange From Baseline in Individual Components of the ACR Core Set - PhGA-VAS - Part B

The investigator gave an overall assessment of the severity of the participant's disease activity. The physician's response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as "no arthritis activity" and the right end (100 mm) marked as "extremely active arthritis." A negative change indicated a lessening in the severity of the participant's disease activity.

Time frame:
Baseline, Week 64
Reported as:
Mean · mm
Change From Baseline in Individual Components of the ACR Core Set - PhGA-VAS - Part B
mmPlacebo/160 mg LY2439821 (bDMARD-naive Population)3 mg/160 mg LY2439821 (bDMARD-naive Population)10 mg/160 mg LY2439821 (bDMARD-naive Population)30 mg/160 mg LY2439821 (bDMARD-naive Population)80 mg/160 mg LY2439821 (bDMARD-naive Population)180 mg/160 mg LY2439821 (bDMARD-naive Population)Placebo/160 mg LY2439821 (TNFα-IR Population)80 mg/160 mg LY2439821 (TNFα-IR Population)180 mg/160 mg LY2439821 (TNFα-IR Population)
Change From Baseline in Individual Components of the ACR Core Set - PhGA-VAS - Part B-36.1 ± 21.7-30.1 ± 22.0-38.5 ± 28.4-38.0 ± 18.5-31.0 ± 20.7-44.4 ± 17.7-30.1 ± 22.5-28.9 ± 25.8-32.7 ± 25.2
SecondaryChange From Baseline in Individual Components of the ACR Core Set - CRP - Part A

CRP is a biological marker of disease activity. A negative change indicated an improvement in participant's disease activity.

Time frame:
Baseline, up to Week 12
Reported as:
Mean · mg/L
Change From Baseline in Individual Components of the ACR Core Set - CRP - Part A
mg/LPlacebo (bDMARD-naive Population)3 mg LY2439821 (bDMARD-naive Population)10 mg LY2439821 (bDMARD-naive Population)30 mg LY2439821 (bDMARD-naive Population)80 mg LY2439821 (bDMARD-naive Population)180 mg LY2439821 (bDMARD-naive Population)Placebo (TNFα-IR Population)80 mg LY2439821 (TNFα-IR Population)180 mg LY2439821 (TNFα-IR Population)
Change From Baseline in Individual Components of the ACR Core Set - CRP - Part A-1.575 ± 22.336-6.079 ± 10.289-9.435 ± 23.148-7.999 ± 14.740-11.968 ± 19.792-13.575 ± 25.6921.229 ± 14.811-9.521 ± 20.312-8.297 ± 21.955
Statistical analysis
  • Placebo (bDMARD-naive Population) vs 3 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = <0.001 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 10 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.012 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 30 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = <0.001 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 80 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = <0.001 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 180 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = <0.001 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (TNFα-IR Population) vs 80 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = <0.001 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (TNFα-IR Population) vs 180 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = 0.001 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
SecondaryChange From Baseline in Individual Components of the ACR Core Set - CRP - Part B

CRP is a biological marker of disease activity. A negative change indicated an improvement in participant's disease activity.

Time frame:
Baseline, Week 64
Reported as:
Mean · mg/L
Change From Baseline in Individual Components of the ACR Core Set - CRP - Part B
mg/LPlacebo/160 mg LY2439821 (bDMARD-naive Population)3 mg/160 mg LY2439821 (bDMARD-naive Population)10 mg/160 mg LY2439821 (bDMARD-naive Population)30 mg/160 mg LY2439821 (bDMARD-naive Population)80 mg/160 mg LY2439821 (bDMARD-naive Population)180 mg/160 mg LY2439821 (bDMARD-naive Population)Placebo/160 mg LY2439821 (TNFα-IR Population)80 mg/160 mg LY2439821 (TNFα-IR Population)180 mg/160 mg LY2439821 (TNFα-IR Population)
Change From Baseline in Individual Components of the ACR Core Set - CRP - Part B-10.548 ± 18.555-4.556 ± 12.937-11.340 ± 23.347-7.865 ± 22.607-14.519 ± 19.260-6.860 ± 16.745-12.094 ± 28.917-10.130 ± 18.030-9.004 ± 19.698
SecondaryPercentage of Participants in European League Against Rheumatism Responder Index (EULAR) 28 - Part A

Assessment of participant's rheumatoid arthritis (RA) by the EULAR that is based on the DAS 28 joint count. Participants were categorized as non-responders or responders (moderate responders + good responders). Percentage of participants was calculated as: (number of responders / number of participants) \* 100.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants in European League Against Rheumatism Responder Index (EULAR) 28 - Part A
percentage of participantsPlacebo (bDMARD-naive Population)3 mg LY2439821 (bDMARD-naive Population)10 mg LY2439821 (bDMARD-naive Population)30 mg LY2439821 (bDMARD-naive Population)80 mg LY2439821 (bDMARD-naive Population)180 mg LY2439821 (bDMARD-naive Population])Placebo (TNFα-IR Population)80 mg LY2439821 (TNFα-IR Population)180 mg LY2439821 (TNFα-IR Population)
Percentage of Participants in European League Against Rheumatism Responder Index (EULAR) 28 - Part A44.467.560.075.773.275.736.560.065.5
Statistical analysis
  • Placebo (bDMARD-naive Population) vs 3 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.013 (P-value is for Week 12 LOCF.)
  • Placebo (bDMARD-naive Population) vs 10 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.076 (P-value is for Week 12 LOCF.)
  • Placebo (bDMARD-naive Population) vs 30 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.002 (P-value is for Week 12 LOCF.)
  • Placebo (bDMARD-naive Population) vs 80 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = <0.001 (P-value is for Week 12 LOCF.)
  • Placebo (bDMARD-naive Population) vs 180 mg LY2439821 (bDMARD-naive Population]) · Fisher Exact · p = 0.002 (P-value is for Week 12.)
  • Placebo (TNFα-IR Population) vs 80 mg LY2439821 (TNFα-IR Population) · Fisher Exact · p = 0.006 (P-value is for Week 12 LOCF.)
  • Placebo (TNFα-IR Population) vs 180 mg LY2439821 (TNFα-IR Population) · Fisher Exact · p = 0.001 (P-value is for Week 12.)
SecondaryPercentage of Participants in EULAR28 - Part B

Assessment of participant's RA by the EULAR that is based on the DAS28 joint count. Participants were categorized as non-responders or responders (moderate responders + good responders). Percentage of participants was calculated as: (number of responders / number of participants) \* 100.

Time frame:
Week 64
Reported as:
Number · percentage of participants
Percentage of Participants in EULAR28 - Part B
percentage of participantsPlacebo/160 mg LY2439821 (bDMARD-naive Population)3 mg/160 mg LY2439821 (bDMARD-naive Population)10 mg/160 mg LY2439821 (bDMARD-naive Population)30 mg/160 mg LY2439821 (bDMARD-naive Population)80 mg/160 mg LY2439821 (bDMARD-naive Population)180 mg/160 mg LY2439821 (bDMARD-naive Population)Placebo/160 mg LY2439821 (TNFα-IR Population)80 mg/160 mg LY2439821 (TNFα-IR Population)180 mg/160 mg LY2439821 (TNFα-IR Population)
Percentage of Participants in EULAR28 - Part B90.281.882.183.984.188.564.573.269.7
SecondaryACR-N - Part A

ACR-N was a continuous measure of clinical, laboratory and functional outcomes in RA that characterized the percentage of improvement in RA disease activity from baseline. The index was defined as the lowest of either: the percent change in TJC, the percent change in SJC, or the median percent change of the remaining 5 ACR core criteria: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. For each criterion, percent change was calculated as: \[(post baseline value - baseline value) / baseline value\] \* 100.

Time frame:
Week 12
Reported as:
Mean · units on a scale
ACR-N - Part A
units on a scalePlacebo (bDMARD-naive Population)3 mg LY2439821 (bDMARD-naive Population)10 mg LY2439821 (bDMARD-naive Population)30 mg LY2439821 (bDMARD-naive Population)80 mg LY2439821 (bDMARD-naive Population)180 mg LY2439821(bDMARD-naive Population)Placebo (TNFα-IR Population)80 mg LY2439821 (TNFα-IR Population)180 mg LY2439821 (TNFα-IR Population)
ACR-N - Part A-11.034 ± 104.809-0.699 ± 13978615.162 ± 51.13011.137 ± 128.51618.351 ± 41.49323.375 ± 42.173-7.356 ± 45.7242.264 ± 59.27711.541 ± 49.358
Statistical analysis
  • Placebo (bDMARD-naive Population) vs 3 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.307 (P-value is for Week 12.)
  • Placebo (bDMARD-naive Population) vs 10 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.104 (P-value is for Week 12.)
  • Placebo (bDMARD-naive Population) vs 30 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.139 (P-value is for Week 12.)
  • Placebo (bDMARD-naive Population) vs 80 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.056 (P-value is for Week 12.)
  • Placebo (bDMARD-naive Population) vs 180 mg LY2439821(bDMARD-naive Population) · ANCOVA · p = 0.048 (P-value is for Week 12.)
  • Placebo (TNFα-IR Population) vs 80 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = 0.160 (P-value is for Week 12.)
  • Placebo (TNFα-IR Population) vs 180 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = 0.029 (P-value is for Week 12.)
SecondaryACR-N - Part B

ACR-N was a continuous measure of clinical, laboratory and functional outcomes in RA that characterized the percentage of improvement in RA disease activity from baseline. The index was defined as the lowest of either: the percent change in TJC, the percent change in SJC, or the median percent change of the remaining 5 ACR core criteria: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. For each criterion, percent change was calculated as: \[(post baseline value - baseline value)/baseline value\] \* 100.

Time frame:
Week 64
Reported as:
Mean · units on a scale
ACR-N - Part B
units on a scalePlacebo/160 mg LY2439821 (bDMARD-naive Population)3 mg/160 mg LY2439821 (bDMARD-naive Population)10 mg/160 mg LY2439821 (bDMARD-naive Population)30 mg/160 mg LY2439821 (bDMARD-naive Population)80 mg LY2439821 (bDMARD-naive Population)180 mg LY2439821 (bDMARD-naive Population)Placebo (TNFα-IR Population)80 mg LY2439821 (TNFα-IR Population)180 mg LY2439821 (TNFα-IR Population)
ACR-N - Part B36.839 ± 42.24133.154 ± 32.43939.922 ± 37.93034.847 ± 69.41038.996 ± 30.71549.152 ± 31.54422.230 ± 54.68214.389 ± 45.46130.891 ± 41.415
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale - Part A

The FACIT Fatigue Scale was a brief participant-reported questionnaire measure of fatigue and consisted of 13 items that assessed tiredness, weakness and difficulty conducting usual activities due to fatigue. Each question was scored on a 5-point scale from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue. For missing data, scores were prorated using the average of the other answers in the scales as long as more than 50% of the items were answered. A negative change indicated less fatigue.

Time frame:
Baseline, up to Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale - Part A
units on a scalePlacebo (bDMARD-naive Population)3 mg LY2439821 (bDMARD-naive Population)10 mg LY2439821 (bDMARD-naive Population)30 mg LY2439821 (bDMARD-naive Population)80 mg LY2439821 (bDMARD-naive Population)180 mg LY2439821(bDMARD-naive Population)Placebo (TNFα-IR Population)80 mg LY2439821 (TNFα-IR Population)180 mg LY2439821 (TNFα-IR Population)
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale - Part A5.566 ± 9.1685.725 ± 8.7066.057 ± 13.5128.924 ± 9.4697.250 ± 9.2455.838 ± 7.9464.953 ± 9.1524.400 ± 8.0686.627 ± 8.401
Statistical analysis
  • Placebo (bDMARD-naive Population) vs 3 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.272 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 10 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.962 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 30 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.236 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 80 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.316 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 180 mg LY2439821(bDMARD-naive Population) · ANCOVA · p = 0.138 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (TNFα-IR Population) vs 80 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = 0.975 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (TNFα-IR Population) vs 180 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = 0.079 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
SecondaryChange From Baseline in FACIT Fatigue Scale - Part B

The FACIT-Fatigue Scale was a brief participant-reported questionnaire measure of fatigue and consisted of 13 items that assessed tiredness, weakness and difficulty conducting usual activities due to fatigue. Each question was scored on a 5-point scale from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue. For missing data, scores were prorated using the average of the other answers in the scales as long as more than 50% of the items were answered. A negative change indicated less fatigue.

Time frame:
Baseline, Week 64
Reported as:
Mean · units on a scale
Change From Baseline in FACIT Fatigue Scale - Part B
units on a scalePlacebo/160 mg LY2439821 (bDMARD-naive Population)3 mg/160 mg LY2439821 (bDMARD-naive Population)10 mg/160 mg LY2439821 (bDMARD-naive Population)30 mg/160 mg LY2439821 (bDMARD-naive Population)80 mg/160 mg LY2439821 (bDMARD-naive Population)180 mg/160 mg LY2439821 (bDMARD-naive Population)Placebo/160 mg LY2439821 (TNFα-IR Population)80 mg/160 mg LY2439821 (TNFα-IR Population)180 mg/160 mg LY2439821 (TNFα-IR Population)
Change From Baseline in FACIT Fatigue Scale - Part B8.390 ± 8.4054.879 ± 10.8108.500 ± 12.8809.177 ± 11.6377.295 ± 10.4366.038 ± 9.9868.323 ± 9.3044.341 ± 8.4936.647 ± 9.639
SecondaryChange From Baseline in Duration of Morning Stiffness (Minutes) - Part A

The investigator queried the participants about the duration of morning stiffness in and around their joints and the results (in minutes) were recorded by the investigator. Duration was the time from when the participants woke up to when normal activities could be resumed. Durations recorded as longer than 12 hours (720 minutes) were summarized as 720 minutes. An increase in duration from baseline indicated a joint worsening and a decrease from baseline indicated joint improvement.

Time frame:
Baseline, up to Week 12
Reported as:
Mean · minutes
Change From Baseline in Duration of Morning Stiffness (Minutes) - Part A
minutesPlacebo (bDMARD-naive Population)3 mg LY2439821 (bDMARD-naive Population)10 mg LY2439821 (bDMARD-naive Population)30 mg LY2439821 (bDMARD-naive Population)80 mg LY2439821 (bDMARD-naive Population)180 mg LY2439821(bDMARD-naive Population)Placebo (TNFα-IR Population)80 mg LY2439821 (TNFα-IR Population)180 mg LY2439821 (TNFα-IR Population)
Change From Baseline in Duration of Morning Stiffness (Minutes) - Part A-36.6 ± 123.7-24.3 ± 87.3-52.7 ± 142.0-71.4 ± 143.9-63.0 ± 57.0-69.0 ± 64.1-36.3 ± 137.7-62.0 ± 138.1-43.1 ± 116.7
Statistical analysis
  • Placebo (bDMARD-naive Population) vs 3 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.982 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 10 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.276 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 30 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.050 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 80 mg LY2439821 (bDMARD-naive Population) · ANCOVA · p = 0.010 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (bDMARD-naive Population) vs 180 mg LY2439821(bDMARD-naive Population) · ANCOVA · p = 0.046 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (TNFα-IR Population) vs 80 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = 0.017 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
  • Placebo (TNFα-IR Population) vs 180 mg LY2439821 (TNFα-IR Population) · ANCOVA · p = 0.066 (P-value is for Week 12.)ANCOVA adjusted for treatment and baseline value.
SecondaryChange From Baseline in Duration of Morning Stiffness (Minutes) - Part B

The investigator queried the participants about the duration of morning stiffness in and around their joints and the results (in minutes) were recorded by the investigator. Duration was the time from when the participants woke up to when normal activities could be resumed. Durations recorded as longer than 12 hours (720 minutes) were summarized as 720 minutes. An increase in duration from baseline indicated a joint worsening and a decrease from baseline indicated joint improvement.

Time frame:
Baseline, Week 64
Reported as:
Mean · minutes
Change From Baseline in Duration of Morning Stiffness (Minutes) - Part B
minutesPlacebo/160 mg LY2439821(bDMARD-naive Population)3 mg/160 mg LY2439821 (bDMARD-naive Population)10 mg/160 mg LY2439821 (bDMARD-naive Population)30 mg/160 mg LY2439821 (bDMARD-naive Population)80 mg/160 mg LY2439821 (bDMARD-naive Population)180 mg/160 mg LY2439821 (bDMARD-naive Population)Placebo/160 mg LY2439821 (TNFα-IR Population)80 mg/160 mg LY2439821 (TNFα-IR Population)180 mg/160 mg LY2439821 (TNFα-IR Population)
Change From Baseline in Duration of Morning Stiffness (Minutes) - Part B-92.1 ± 111.3-70.2 ± 112.3-55.6 ± 72.9-92.3 ± 136.7-68.8 ± 72.5-82.3 ± 79.2-61.3 ± 161.9-60.9 ± 164.7-85.9 ± 74.8
SecondaryChange From Baseline in HAQ-DI - Part A

HAQ-DI was a participant-reported questionnaire that consisted of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 disability domains were required to compute the participant's HAQ-DI score. If the participant had scores for fewer than 6 categories, the HAQ-DI score was considered missing. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, with a possible scores range of 0 to 3. Negative mean changes from baseline indicated improvement.

Time frame:
Baseline, up to Week 12
Reported as:
Mean · units on a scale
Change From Baseline in HAQ-DI - Part A
units on a scalePlacebo (bDMARD-naive Population)3 mg LY2439821 (bDMARD-naive Population)10 mg LY2439821 (bDMARD-naive Population)30 mg LY2439821 (bDMARD-naive Population)80 mg LY2439821 (bDMARD-naive Population)180 mg LY2439821(bDMARD-naive Population)Placebo (TNFα-IR Population)80 mg LY2439821 (TNFα-IR Population)180 mg LY2439821 (TNFα-IR Population)
Change From Baseline in HAQ-DI - Part A-0.220 ± 0.459-0.322 ± 0.493-0.418 ± 0.693-0.537 ± 0.639-0.469 ± 0.517-0.476 ± 0.655-0.182 ± 0.458-0.223 ± 0.448-0.265 ± 0.496
Statistical analysis
  • Placebo (bDMARD-naive Population) vs 3 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.538 (P-value is for Week 12.)
  • Placebo (bDMARD-naive Population) vs 10 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.515 (P-value is for Week 12.)
  • Placebo (bDMARD-naive Population) vs 30 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.030 (P-value is for Week 12.)
  • Placebo (bDMARD-naive Population) vs 80 mg LY2439821 (bDMARD-naive Population) · Fisher Exact · p = 0.053 (P-value is for Week 12.)
  • Placebo (bDMARD-naive Population) vs 180 mg LY2439821(bDMARD-naive Population) · Fisher Exact · p = 0.393 (P-value is for Week 12.)
  • Placebo (TNFα-IR Population) vs 80 mg LY2439821 (TNFα-IR Population) · Fisher Exact · p = 0.077 (P-value is for Week 12.)
  • Placebo (TNFα-IR Population) vs 180 mg LY2439821 (TNFα-IR Population) · Fisher Exact · p = 0.105 (P-value is for Week 12.)
SecondaryChange From Baseline in HAQ-DI - Part B

HAQ-DI was a participant-reported questionnaire that consisted of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 disability domains were required to compute the participant's HAQ-DI score. If the participant had scores for fewer than 6 categories, the HAQ-DI score was considered missing. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3. Negative mean changes from baseline indicated improvement.

Time frame:
Baseline, Week 64
Reported as:
Mean · units on a scale
Change From Baseline in HAQ-DI - Part B
units on a scalePlacebo/160 mg LY2439821 (bDMARD-naive Population)3 mg/160 mg LY2439821 (bDMARD-naive Population)10 mg/160 mg LY2439821 (bDMARD-naive Population)30 mg/160 mg LY2439821 (bDMARD-naive Population)80 mg/160 mg LY2439821 (bDMARD-naive Population)180 mg/160 mg LY2439821 (bDMARD-naive Population)Placebo/160 mg LY2439821 (TNFα-IR Population)80 mg/160 mg LY2439821 (TNFα-IR Population)180 mg/160 mg LY2439821 (TNFα-IR Population)
Change From Baseline in HAQ-DI - Part B-0.616 ± 0.609-0.542 ± 0.611-0.665 ± 0.662-0.673 ± 0.705-0.554 ± 0.614-0.697 ± 0.571-0.331 ± 0.449-0.250 ± 0.460-0.309 ± 0.437
SecondaryRelationship Between Exposure and Response of Individual Components of the ACR Core Set
Time frame:
Through Week 72

No measurements were reported for this outcome.

SecondaryRelationship Between Exposure and Response of ACR20/50/70/N
Time frame:
Through Week 72

No measurements were reported for this outcome.

SecondaryRelationship Between Exposure and Response of DAS28
Time frame:
Through Week 72

No measurements were reported for this outcome.

SecondaryRelationship Between Exposure and Response of EULAR28
Time frame:
Through Week 72

No measurements were reported for this outcome.

SecondaryPharmacokinetics (PK): Maximum Concentration (Cmax) of LY2439821 at Steady State

Evaluable PK concentrations from all time points, including data from placebo participants who elected active treatment in Part B, were combined and utilized in a population approach to determine the population median estimates and 90% confidence intervals at steady state. Day 0 and Week 6 postdose samples were collected as late as possible during the dosing visit (in other words, the postdose samples were collected at the end of their respective visits).

Time frame:
Predose: Day 0, Day 1 or 2 or 3, Day 7, Weeks 6, 10, 16, 40 and 64 and Postdose: Day 0 and Week 6
Reported as:
Median · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2439821 at Steady State
nanograms per milliliter (ng/mL)Part A: 3 mg LY2439821 (bDMARD-naive Population)Part A: 10 mg LY2439821 (bDMARD-naive Population)Part A: 30 mg LY2439821 (bDMARD-naive Population)Part A: 80 mg LY2439821 (bDMARD-naive Population)Part A: 180 mg LY2439821(bDMARD-naive Population)Part A: 80 mg LY2439821 (TNFα-IR Population)Part A: 180 mg LY2439821 (TNFα-IR Population)Part B: 160 mg LY2439821 (bDMARD-naive and TNFα-IR Population)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2439821 at Steady State336 (138 to 783)1060 (352 to 2580)3230 (1140 to 7970)7580 (2590 to 18600)17100 (6870 to 42000)7320 (2740 to 17700)16200 (6040 to 40600)18600 (8040 to 45000)
SecondaryPercentage of Participants With Anti-LY2439821 Antibodies

Treatment-emergent anti-LY2439821 antibody positive participants were defined as a titer change from baseline that was at least 2 dilutions (4-fold) increase. Participants must have had an assessment to be classified as treatment emergent antibody positive or negative.

Time frame:
Week 16, Week 64
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-LY2439821 Antibodies
percentage of participantsPlacebo (bDMARD-naive Population)3 mg LY2439821 (bDMARD-naive Population)10 mg LY2439821 (bDMARD-naive Population)30 mg LY2439821 (bDMARD-naive Population)80 mg LY2439821 (bDMARD-naive Population)180 mg LY2439821(bDMARD-naive Population)Placebo (TNFα-IR Population)80 mg LY2439821 (TNFα-IR Population)180 mg LY2439821 (TNFα-IR Population)
Part A Week 16 (n=43,35,34,35,49,33,52,57,51)11.614.38.88.616.315.27.710.513.7
Part B Week 64 (n=37,32,28,30,40,26,31,41,33)0.00.03.60.02.53.86.50.09.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
3 mg LY2439821 (bDMARD-naive Population) Part A—0/40 (0%)16/40 (40%)
10 mg LY2439821 (bDMARD-naive Population) Part A—1/35 (2.9%)16/35 (45.7%)
30 mg LY2439821 (bDMARD-naive Population) Part A—1/37 (2.7%)16/37 (43.2%)
80 mg LY2439821 (bDMARD-naive Population) Part A—4/57 (7%)23/57 (40.4%)
180 mg LY2439821(bDMARD-naive Population) Part A—1/37 (2.7%)16/37 (43.2%)
Placebo (bDMARD-naive Population) Part A—1/54 (1.9%)22/54 (40.7%)
80 mg LY2439821 (TNFa-IR Population) Part A—5/65 (7.7%)31/65 (47.7%)
180 mg LY2439821 (TNFa-IR Population) Part A—6/59 (10.2%)32/59 (54.2%)
Placebo (TNFa-IR Population) Part A—1/64 (1.6%)32/64 (50%)
3 mg/160 mg LY2439821 (bDMARD-naive Population) Part B—3/36 (8.3%)14/36 (38.9%)
10 mg/160 mg LY2439821 (bDMARD-naive Population) Part B—3/33 (9.1%)19/33 (57.6%)
30 mg/160 mg LY2439821 (bDMARD-naive Population) Part B—2/34 (5.9%)12/34 (35.3%)
80 mg/160 mg LY2439821 (bDMARD-naive Population) Part B—4/51 (7.8%)23/51 (45.1%)
180 mg/160 mg LY2439821 (bDMARD-naive Population) Part B—1/32 (3.1%)16/32 (50%)
Placebo/160 mg LY2439821 (bDMARD-naive Population) Part B—4/46 (8.7%)26/46 (56.5%)
80 mg/160 mg LY2439821 (TNFa-IR Population) Part B—7/57 (12.3%)23/57 (40.4%)
180 mg/160 mg LY2439821 (TNFa-IR Population) Part B—4/50 (8%)16/50 (32%)
Placebo/160 mg LY2439821 (TNFa-IR Population) Part B—7/51 (13.7%)23/51 (45.1%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
Event3 mg LY2439821 (bDMARD-naive Population) Part A10 mg LY2439821 (bDMARD-naive Population) Part A30 mg LY2439821 (bDMARD-naive Population) Part A80 mg LY2439821 (bDMARD-naive Population) Part A180 mg LY2439821(bDMARD-naive Population) Part APlacebo (bDMARD-naive Population) Part A80 mg LY2439821 (TNFa-IR Population) Part A180 mg LY2439821 (TNFa-IR Population) Part APlacebo (TNFa-IR Population) Part A3 mg/160 mg LY2439821 (bDMARD-naive Population) Part B10 mg/160 mg LY2439821 (bDMARD-naive Population) Part B30 mg/160 mg LY2439821 (bDMARD-naive Population) Part B80 mg/160 mg LY2439821 (bDMARD-naive Population) Part B180 mg/160 mg LY2439821 (bDMARD-naive Population) Part BPlacebo/160 mg LY2439821 (bDMARD-naive Population) Part B80 mg/160 mg LY2439821 (TNFa-IR Population) Part B180 mg/160 mg LY2439821 (TNFa-IR Population) Part BPlacebo/160 mg LY2439821 (TNFa-IR Population) Part B
MeningitisInfections and infestations0/400/350/370/570/370/540/650/590/640/360/330/340/511/320/460/570/500/51
Pancreatitis acuteGastrointestinal disorders0/400/350/370/570/370/540/650/590/640/361/331/340/510/320/461/570/500/51
DeathGeneral disorders0/400/350/370/570/370/540/650/590/640/361/330/340/510/320/460/570/500/51
Urinary tract infectionInfections and infestations0/400/350/370/570/370/540/650/590/640/361/330/340/510/320/460/570/500/51
Aortic aneurysmVascular disorders0/401/350/370/570/370/540/650/590/640/361/330/340/510/320/460/570/500/51
PneumoniaInfections and infestations0/400/350/370/570/370/541/650/590/640/360/331/341/510/320/460/570/500/51
PneumoconiosisInjury, poisoning and procedural complications0/400/350/370/570/370/540/650/590/640/360/331/340/510/320/460/570/500/51
Pyelonephritis acuteInfections and infestations0/400/350/370/570/370/540/650/590/641/360/330/340/510/320/460/570/500/51
Femur fractureInjury, poisoning and procedural complications0/400/350/370/570/370/540/650/590/641/360/330/340/510/320/460/570/500/51
Intracranial aneurysmNervous system disorders0/400/350/370/570/370/540/650/590/641/360/330/340/510/320/460/570/500/51
Most frequent other events
Showing 10 of 48
Most frequent other events
Event3 mg LY2439821 (bDMARD-naive Population) Part A10 mg LY2439821 (bDMARD-naive Population) Part A30 mg LY2439821 (bDMARD-naive Population) Part A80 mg LY2439821 (bDMARD-naive Population) Part A180 mg LY2439821(bDMARD-naive Population) Part APlacebo (bDMARD-naive Population) Part A80 mg LY2439821 (TNFa-IR Population) Part A180 mg LY2439821 (TNFa-IR Population) Part APlacebo (TNFa-IR Population) Part A3 mg/160 mg LY2439821 (bDMARD-naive Population) Part B10 mg/160 mg LY2439821 (bDMARD-naive Population) Part B30 mg/160 mg LY2439821 (bDMARD-naive Population) Part B80 mg/160 mg LY2439821 (bDMARD-naive Population) Part B180 mg/160 mg LY2439821 (bDMARD-naive Population) Part BPlacebo/160 mg LY2439821 (bDMARD-naive Population) Part B80 mg/160 mg LY2439821 (TNFa-IR Population) Part B180 mg/160 mg LY2439821 (TNFa-IR Population) Part BPlacebo/160 mg LY2439821 (TNFa-IR Population) Part B
Benign prostatic hyperplasiaReproductive system and breast disorders0/70/80/60/50/70/70/80/80/90/70/80/50/50/71/60/80/50/6
NasopharyngitisInfections and infestations2/402/350/373/573/373/543/651/594/643/364/333/342/513/325/466/571/501/51
Injection site painGeneral disorders1/401/351/372/572/371/546/657/593/641/361/331/342/510/324/460/571/505/51
HeadacheNervous system disorders0/404/352/372/571/376/547/652/595/641/361/330/342/511/322/462/572/503/51
Upper respiratory tract infectionInfections and infestations1/400/353/373/572/370/544/656/597/640/360/330/340/510/320/460/570/500/51
CoughRespiratory, thoracic and mediastinal disorders2/400/351/370/570/370/541/651/590/640/360/332/343/513/322/460/571/502/51
Injection site erythemaGeneral disorders2/400/350/370/570/370/543/655/592/642/362/330/342/510/321/463/574/503/51
Injection site haematomaGeneral disorders0/400/350/371/570/370/541/655/590/640/360/330/340/510/321/460/570/501/51
Urinary tract infectionInfections and infestations1/402/353/372/572/374/544/655/592/640/360/330/340/510/320/460/570/500/51
Rheumatoid arthritisMusculoskeletal and connective tissue disorders1/402/352/372/570/371/543/655/592/640/360/330/340/510/320/460/570/500/51

Baseline characteristics

Full Analysis Set (FAS): All randomized participants who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)Placebo [bDMARD-naive Population]3 mg LY2439821 [bDMARD-naive Population]10 mg LY2439821 [bDMARD-naive Population]30 mg LY2439821 [bDMARD-naive Population80 mg LY2439821 [bDMARD-naive Population]180 mg LY2439821[bDMARD-naive Population]Placebo [TNFα-IR Population]80 mg LY2439821 [TNFα-IR Population]180 mg LY2439821 [TNFα-IR Population]Total
<=18 years0000000000
Between 18 and 65 years453730294832595552387
>=65 years935895510761
Age, Continuous
Age, Continuous(years)Placebo [bDMARD-naive Population]3 mg LY2439821 [bDMARD-naive Population]10 mg LY2439821 [bDMARD-naive Population]30 mg LY2439821 [bDMARD-naive Population80 mg LY2439821 [bDMARD-naive Population]180 mg LY2439821[bDMARD-naive Population]Placebo [TNFα-IR Population]80 mg LY2439821 [TNFα-IR Population]180 mg LY2439821 [TNFα-IR Population]Total
Mean52.99 ± 10.1852.19 ± 9.6753.86 ± 10.6253.03 ± 12.1652.60 ± 10.9152.21 ± 11.3353.19 ± 10.4454.74 ± 11.1252.43 ± 9.9053.08 ± 10.61
Sex: Female, Male
Sex: Female, Male(Participants)Placebo [bDMARD-naive Population]3 mg LY2439821 [bDMARD-naive Population]10 mg LY2439821 [bDMARD-naive Population]30 mg LY2439821 [bDMARD-naive Population80 mg LY2439821 [bDMARD-naive Population]180 mg LY2439821[bDMARD-naive Population]Placebo [TNFα-IR Population]80 mg LY2439821 [TNFα-IR Population]180 mg LY2439821 [TNFα-IR Population]Total
Female473327315230555751383
Male77865798865
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo [bDMARD-naive Population]3 mg LY2439821 [bDMARD-naive Population]10 mg LY2439821 [bDMARD-naive Population]30 mg LY2439821 [bDMARD-naive Population80 mg LY2439821 [bDMARD-naive Population]180 mg LY2439821[bDMARD-naive Population]Placebo [TNFα-IR Population]80 mg LY2439821 [TNFα-IR Population]180 mg LY2439821 [TNFα-IR Population]Total
Hispanic or Latino9787106152315100
Not Hispanic or Latino453224294630484143338
Unknown or Not Reported01311111110
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo [bDMARD-naive Population]3 mg LY2439821 [bDMARD-naive Population]10 mg LY2439821 [bDMARD-naive Population]30 mg LY2439821 [bDMARD-naive Population80 mg LY2439821 [bDMARD-naive Population]180 mg LY2439821[bDMARD-naive Population]Placebo [TNFα-IR Population]80 mg LY2439821 [TNFα-IR Population]180 mg LY2439821 [TNFα-IR Population]Total
American Indian or Alaska Native23212400216
Asian16131012171034388
Native Hawaiian or Other Pacific Islander0000000000
Black or African American42013162423
White292021203122545850305
More than one race32234011016
Unknown or Not Reported0000000000
Region of Enrollment
Region of Enrollment(participants)Placebo [bDMARD-naive Population]3 mg LY2439821 [bDMARD-naive Population]10 mg LY2439821 [bDMARD-naive Population]30 mg LY2439821 [bDMARD-naive Population80 mg LY2439821 [bDMARD-naive Population]180 mg LY2439821[bDMARD-naive Population]Placebo [TNFα-IR Population]80 mg LY2439821 [TNFα-IR Population]180 mg LY2439821 [TNFα-IR Population]Total
United States12988129333231154
Taiwan54344311126
Argentina10011010111034
Poland118879711111082
Romania54346311027
Peru64446411131
Chile01202212111
Russian Federation31013211113
Germany0000103228
Korea, Republic of22112123216
India976711600046
08

Study locations

75 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Peoria, Arizona 85381, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    La Mesa, California 91942, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Palm Desert, California 92260, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Jose, California 95126, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santa Maria, California 93454, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stanford, California 94305, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Westlake Village, California 91361, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Denver, Colorado 80230, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Washington, District of Columbia 20003, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lake Mary, Florida 32746, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Melbourne, Florida 32901, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sarasota, Florida 34239, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St. Petersburg, Florida 33710, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tampa, Florida 33614, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vero Beach, Florida 32962, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Decatur, Georgia 30329, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rome, Georgia 30165, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Idaho Falls, Idaho 83404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Springfield, Illinois 62704, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cumberland, Maryland 21502, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Frederick, Maryland 21702, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wheaton, Maryland 20902, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bingham Farms, Michigan 48025, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Louis, Missouri 63117, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wilmington, North Carolina 28401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tulsa, Oklahoma 74135, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bethlehem, Pennsylvania 18017, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sellersville, Pennsylvania 18960, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Charleston, South Carolina 29407, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Memphis, Tennessee 38119, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sugar Land, Texas 77479, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Temple, Texas 76508, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salt Lake City, Utah 84143, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Arlington, Virginia 22205, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Olympia, Washington 98502, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Spokane, Washington 99202, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milwaukee, Wisconsin 53217, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, C1425AWC, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Quilmes, B1878DVC, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, 05400, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tucuman, 4000, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santiago, Chile
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Freiburg, 79106, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 22415, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hohenfelde, 18209, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tubingen, D-72076, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bangalore, 560079, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyderabaad, 500082, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jaipur, 302023, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Secunderabad, 500 003, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Daejeon, 302-799, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pusan, 602-739, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 150-713, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Arequipa, Peru
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lima, Lima 27, Peru
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pueblo Libre, Lima 21, Peru
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bytom, 41-902, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Czestochowa, 42-200, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Konskie, 26-200, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Koscian, 64-000, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Krakow, 30-510, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Poznan, 60-773, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Torun, 87-100, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 02-507, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Baia Mare, 430110, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucharest, 10584, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cluj-Napoca, 400006, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Iasi, 700656, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Moscow, 115522, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Petersburg, 115522, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kaohsiung County, 833, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taichung City, 40201, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taichung, 404, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, 100, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tao-Yuan, 333, Taiwan
09

References and documents

Publications

  • Genovese MC, Braun DK, Erickson JS, Berclaz PY, Banerjee S, Heffernan MP, Carlier H. Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis. J Rheumatol. 2016 Feb;43(2):289-97. doi: 10.3899/jrheum.140831. Epub 2015 Dec 15. PubMed 26669919 ↗
  • Genovese MC, Greenwald M, Cho CS, Berman A, Jin L, Cameron GS, Benichou O, Xie L, Braun D, Berclaz PY, Banerjee S. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2014 Jul;66(7):1693-704. doi: 10.1002/art.38617. PubMed 24623718 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2009, a primary completion of Mar 2011 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 5 years 2 months after primary completion. A results delay was requested in Aug 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2009
First posted
Aug 27, 2009
Start
Aug 2009
Primary completionActual
Mar 2011
CompletionActual
Jun 2012
Results delay requested
Aug 9, 2011
Results first posted
May 26, 2016
Last update
May 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00966875
Responsible party
Sponsor
First posted
Aug 27, 2009
Start date
Aug 2009
Primary completion
Mar 2011
Completion
Jun 2012
Results posted
May 26, 2016
Last update
May 26, 2016

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT-5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion